Board of Directors

	Fuminori Yoshida Reprentative Director Fuminori Yoshida established SymBio Pharmaceuticals Limited, his third company, in March of 2005 in order to address the unmet medical needs of Japanese patients; as founding President of two other major healthcare companies, Nippon BioRad Laboratories (1980) and Amgen Japan (1993), he has earned high visibility and credibility within Japan's healthcare and academic communities. Following his graduation from Gakushuin University in 1971 with a B.S. in Organic Chemistry, he went on to receive an M.S. in Molecular Biology from MIT (1973) and M.S. in Health Policy and Management from Harvard University Graduate School (1975). He possesses dual experience and expertise in the management of major Japanese and American corporations through his work for various companies in the past, such as Mitsubishi Corporation and AHS Japan, Syntex Japan (1993) as President and CEO, serving concurrently at Amgen Japan (presently, Takeda Bio Development Center Ltd.) as President and CEO, and Amgen Inc. as Corporate Vice-President for 12 years until January of 2005. He has retained a high profile within the pharmaceutical industry due to his active involvement in various conferences (e.g. keynote speaker at 1st Bio-Expo), as member of several committees sponsored by the Ministry of Science and Technology, as lecturer at several prestigious colleges (e.g. Waseda University), as author of various publications in reputable pharmaceutical business journals, and as author of two books which were subsequently published in Japan (‘Golden DNA Helix' and ‘A Story of a Biotech Pioneer'). Utilizing his extensive management experience and social network, he has assembled an exceptional management team at SymBio.
	Shigetoshi Matsumoto Board Director<Outside> Shigetoshi Matsumoto graduated from University of Toyama Faculty of Pharmacy and Pharmaceutical Sciences in 1972, and then joined CHUGAI PHARMACEUTICAL CO., LTD. After holding various positions in Sales & Marketing related divisions, he assumed the position of General Manager of the Audit Office (2002), At the Company, he has successively held the positions of Full-time Audit & Supervisory Board Member (2007), and Senior Advisor (2011). He became Advisor to APO PLUS STATION Co., Ltd. in 2011, and then became Senior Advisor to Protiviti LLC in 2015. He currently serves as Audit Practice Counselor, Japan Audit & Supervisory Board Members Association since october 2015. He served as a member of the Audit & Supervisory Board at the Company since March 2017.He serves as board director (Outside) of the company since March 2018.
	Bruce David Cheson Board Director<Outside> Dr. Cheson received his medical degree from Tufts University and completed his residency at University of Virginia Hospitals (1971) and fellowship at New England Medical Center Hospital (1974). Then he assumed Assistant Professor of Medicine, Hematology/Oncology of University of Utah School, University of Utah Hospital (1977), and Senior Investigator and Head of Medicine Section, National Cancer Institute, Cancer Therapy Evaluation Program (1984). He joined Georgetown University Hospital, Lombardi Comprehensive Cancer Center as Deputy Chief, Hematology-Oncology, Head of Hematology (2002), and became Frank M. Ewing Foundation Chair in Hematology-Oncology since 2018, 2001 Scientific Advisory Board, Lymphoma Research Foundation .He had been the external Board of Director of Morphosys since 2016, and he serves as board director (Outside) of the company since March 2019.
	Eiji Ebinuma Board Director<Outside> Eiji Ebinuma graduated from the Faculty of Law, the University of Tokyo in 1980, and completed a Master's degree in law at Sophia University. He joined The Industrial Bank of Japan, Limited (currently Mizuho Bank Ltd.) in 1980 and was promoted to Deputy Head of HR Planning Team of Mizuho Bank, Ltd (2002). In 2003, he became Head of Executive Secretary and General Planning Dept. of Olimpic Corporation. He received his attorney certification and joined Toranomon Sougoh Law Firm in 2008, and he has been a partner at Tanabe & Partners since 2013, and board director of Rakuten Bank Ltd since 2016. He had been a board director of Mirait Holdings in 2014, and Auditor of TOKO ELECTRICAL CONSTRUCTION CO. He had been an Audit & Supervisory Board Member of the company since March 2019. He serves as board director (Outside) of the company since March 2021.
	Toshio Imabeppu Board Director<Outside> Toshio Imabeppu graduated from the University of Tokyo, Faculty of Law in 1981. In the same year, he joined the Ministry of Health and Welfare (now the Ministry of Health, Labour and Welfare), where he served in the Office of Advanced Pharmaceutical Technology Promotion, Cabinet Counselor, Cabinet Secretariat, Director of Insurance Division, Director of Accounting Division, Director of Pharmaceutical and Food Safety Bureau, and Director for Policy Coordination, etc. He retired in 2015 and has been serving as Outside Director of Ship Healthcare Holdings,Inc Corporation since June 2019, President of Japan Regenerative Medicine Association since June 2022, and Representative Director of Japan He has also served as President of the Japanese Society for Regenerative Association and Representative Director of the Judo Repositioning Training and Examination Foundation since June 2022. He has been a Board Director (outside) of the Company since March 2024.
	George Morstyn Board Director<Outside> MD PhD FTSE FRACP MAICD Dr Morstyn has more than 25 years’ experience in the biotechnology industry including as Senior Vice President of Development and Chief Medical Officer at Amgen where he had overall responsibility globally for drug development in all therapeutic areas. Prior to joining Amgen, Dr Morstyn was principal investigator on the earliest clinical studies of the haemopoietic colony stimulating factors. From 2010 to 2016 he was Deputy Chairman of the Victorian Comprehensive Cancer Centre. He is the Chief Executive Officer of G & R Morstyn Pty Ltd. and has served as a board director(Outside) of Symbio from 2009 to 2019. He is currently a non-executive director of Actinogen (ASX listed) and PioTx (Australia). He has been assigned as Chair of Scientific Advisory Board of the company since 2019. Dr. Morstyn has been a board director(Outside) of the Company since March 2024.
	Kiyoshi Watanabe Board Director, Full-Time Audit & Supervisory Committee Member<Outside> Kiyoshi Watanabe graduated from Hitotsubashi University Faculty of Commerce and Management in 1974, and then joined The Industrial Bank of Japan, Limited (currently Mizuho Bank, Ltd.). He completed a Master's degree (MSM) at Purdue University Krannert School of Management. After serving as Chief of The Americas Corporate Credit Office, Credit Department of the Bank from 1998 in New York, he joined Kyowa Hakko Kogyo Co., Ltd. in 2003 as General Manager, Corporate Planning Office. He became General Manager, Medicine Planning Department of the Company in 2005, and then became General Manager, Planning and Administration Department at KYOWA HAKKO BIO CO., LTD. in 2008. He assumed the position of Full-time Audit & Supervisory Board Member at Kawaguchi Chemical Industry Co., Ltd. in 2011 and Audit & Supervisory Board Member at Toho Acetylene Co., Ltd., in 2015. In March 2017, he was appointed Full-time Audit & Supervisory Board Member (Outside) of the Company. In March 2022, he was appointed Board Director, Full-time Audit & Supervisory Committee Member (Outside) of the Company.
	Kesao Endo Board Director, Audit & Supervisory Committee Member<Outside> Kesao Endo received his certification as a Certified Public Accountant in 1983. He joined Price Waterhouse Consultant in 1984. He joined Deloitte and Touche in 1986 and was stationed at Deloitte's Los Angeles and New York offices. He earned his USPCA (United States Certified Public Accountant) in 1991. He served as a member of the Audit & Supervisory Board at Akebono Brake Industry Co., Ltd in 2006. He currently serves outside director of Careerlink Co., Ltd. and is a partner of ABS Audit Corporation. In March 2018, he was appointed Corporate Auditor (Outside) of the Company. In March 2022, he was appointed Board Director, Audit & Supervisory Committee Member (Outside) of the Company.
	Yasuhiro Tamo Board Director, Audit & Supervisory Committee Member<Outside> Yasuhiro Tamo graduated from the Faculty of Law Class II of University of Tokyo in 2000, and then joined The Industrial Bank of Japan, Limited (currently Mizuho Bank, Ltd.). He transferred to Mizuho Corporate Bank, Ltd in 2002. He completed a Master's degree of Department of Legal Profession, Graduate School of Law, at Kyoto University in 2006. He joined Yanagida & Nomura (currently Yanagida & Partners) in 2007, then moved to Nomura & Partners in 2009. He completed LL.M. at University of Michigan Law School in 2016. He has been a partner at Nomura & Partners since 2019. In March 2021, he was appointed Corporate Auditor (Outside) of the Company. In March 2022, he was appointed Board Director, Audit & Supervisory Committee Member (Outside) of the Company.